Ingestion of a Moderately High Caffeine Dose Before Exercise Increases Postexercise Energy Expenditure

Valentín E. Fernández-Elias, Juan Del Coso, Nassim Hamouti, Juan F. Ortega, Gloria Muñoz, Jesus Muñoz-Guerra, and Ricardo Mora-Rodríguez

Caffeine is an ergogenic aid widely used before and during prolonged exercise. Due to its prolonged biological half-life caffeine effects could remain after exercise. We aimed to investigate the metabolic, respiratory, and cardiovascular postexercise responses to preexercise graded caffeine ingestion. Twelve aerobically trained subjects (mean VO\textsubscript{2max} = 54 ± 7 ml · min\textsuperscript{-1} · kg\textsuperscript{-1}) cycled for 60-min at 75% VO\textsubscript{2max} after ingesting placebo (0 mg of caffeine per kg of body weight) or 0.5, 1.5, 3.0 and 4.5 mg · kg\textsuperscript{-1} on five occasions. During the 3 hr postexercise, heart rate, blood pressure, glucose, lactate, and fatty acids were analyzed. None of these variables were statistically affected by preexercise caffeine ingestion between 0.5 and 4.5 mg · kg\textsuperscript{-1}. However, ingestion of 4.5 mg · kg\textsuperscript{-1} of caffeine raised postexercise energy expenditure 15% above placebo (233 ± 58 vs. 202 ± 49 kcal/3 hr, p < .05). Ventilation and tidal volume were elevated after the 4.5 mg·kg\textsuperscript{-1} caffeine dose above placebo (9.2 ± 2.5 L · min\textsuperscript{-1} and 0.67 ± 0.29 L · breath\textsuperscript{-1} vs. 7.8 ± 1.5 L · min\textsuperscript{-1} and 0.56 ± 0.20 L · breath\textsuperscript{-1}, respectively; p < .05). Ventilation correlated with tidal volume (r = .45; p < .05) and energy expenditure (r = .72; p < .05). In summary, preexercise ingestion of ergogenic caffeine doses do not alter postexercise cardiovascular responses. However, ingestion of 4.5 mg · kg\textsuperscript{-1} of caffeine raises 3-hr postexercise energy expenditure (i.e., 31 kcal) likely through increased energy cost of ventilation.

**Keywords:** metabolic rate, ventilation, heart rate

Caffeine (1, 3, 7–trimethylxanthine) is the most used drug worldwide and it can be ingested from natural sources such as coffee, tea or chocolate, or included in cola-soft drinks and energy drinks. Because of the ergogenic properties of caffeine most exercise related research has focused on performance outcomes. However, due to its prolonged biological half-life (5–6 hr (Kamimori et al., 2002)) caffeine ingested to enhance exercise performance could result in metabolic and cardiorespiratory effects postexercise. For instance, a high dose of caffeine ingestion may lead to tachycardia (Cole et al., 1996), elevated blood pressure (Arciero et al., 1998), gastrointestinal problems, nervousness and affect sleep quality after exercise (Pallares et al., 2013). On the other hand, caffeine may improve substrate recovery (Batttram et al., 2004; Pedersen et al., 2008) or could be used to increase postexercise energy expenditure and promote fat loss. Indeed, caffeine is in the main component in several over-the-counter preparations allegedly useful for weight management, although none scientifically proven (Hallas et al., 2008).

The ergogenic effect of caffeine on endurance has been shown when ingesting relatively low doses (1–3 mg · kg\textsuperscript{-1}; Jenkins et al., 2008; Kovacs et al., 1998) and also after ingesting high doses (5–13 mg · kg\textsuperscript{-1}; Pasman et al., 1995). However, Graham and Spriet (1995) found that the minimal caffeine dose that delays time to exhaustion when cycling at high intensity (85% VO\textsubscript{2max}) was 3 mg · kg\textsuperscript{-1}. Kovacs et al., (Kovacs et al., 1998) using a time trial endurance test found that caffeine doses from 2.1 to 4.5 mg · kg\textsuperscript{-1} had a significant ergogenic effect. In addition, resistance sports have been the target of investigations addressing caffeine effects (Astorino et al., 2007, 2011; Mora-Rodriguez et al., 2012; Pallares et al., 2013). We have recently found that caffeine doses from 3 to 9 mg · kg\textsuperscript{-1} have an ergogenic effect during resistance exercise (Pallares et al., 2013). In contrast to the abundant information during exercise, the postexercise effects of different doses of caffeine taken for ergogenic purposes are not well defined.

It has been shown that caffeine ingestion increases resting energy expenditure (REE) (Diepvens et al., 2007;
he conclusions are based on data in two subjects. Astrup et al. (1990) showed that the highest and the lowest caffeine dose (400 and 100 mg) raised RER above placebo but not the intermediate dose (200 mg of caffeine). Hollands and coworkers (Hollands et al., 1981) supplied subjects with 1.5 mg · kg⁻¹ and found 15% elevations in RER during 2 hr after its consumption. In contrast, Arciero et al. (1995) found an increase of 2% in RER after consuming 4.4 mg of caffeine · kg⁻¹ of body mass. Thus, the dose-response relationship between caffeine and RER is not clearly established.

The postexercise effects of caffeine ingestion on the cardiovascular system are also controversial. Studies at rest suggest that caffeine ingestion (i.e., 5 mg · kg⁻¹) rises blood pressure in the elderly population without altering heart rate (Arciero et al., 1998). To our knowledge, only Notarius et al. (2006) and Astorino et al. (2013) investigated the cardiovascular postexercise effects of caffeine ingestion. Notarius et al. (Notarius et al., 2006) intravenously infused 4 mg · kg⁻¹ of caffeine preexercise, and found that 10 min after exercise, arterial pressure, and heart rate were significantly higher than in the placebo trial. On the other hand, Astorino et al. (2013) provided 6 mg · kg⁻¹ orally, preexercise, and did not observe any change in arterial pressure during the 70 min that followed exercise. Therefore, there are contradictory effects of caffeine on postexercise cardiovascular responses and this warrants further investigation.

The purpose of this study was to determine if caffeine ingested preexercise in doses designed to enhance exercise performance, alters postexercise metabolic, cardiovascular and ventilatory responses. A second purpose was to determine for how long those responses will be altered. For that purpose, we monitored blood concentration of different substrates and metabolites, ventilation, heart rate, blood pressure and VO₂ during the 3 hr that followed 60 min of aerobic exercise. To comprehensively address the effects of caffeine we monitored all these variables after ingestion of different caffeine doses. We used doses that have a proven ergogenic endurance effect (3.0 and 4.5 mg · kg⁻¹) and doses that are habitually used by recreational athletes (0.5–1.0 mg · kg⁻¹ from drinking caffeinated colas and energy drinks). To our knowledge, this dose-response design of addressing postexercise caffeine effects is novel and may help to understand RER elevations after caffeine consumption.

**Methods**

**Subjects**

Twelve aerobically trained (~1 hr · day⁻¹, 4–7 days · week⁻¹ of cycling or running) healthy young subjects were recruited to participate in this study. They had a mean ± SD age of 27 ± 8 yrs, body mass of 66 ± 12 kg, height of 171 ± 10 cm, and maximal oxygen uptake (VO₂max) of 54 ± 6 ml · min⁻¹ · kg⁻¹. The group included six women tested always in the luteal phase (Hackney et al., 1991). No participant had previous history of cardiopulmonary or metabolic diseases, or was taking medications during the study. Participants were no-smokers. A validated caffeine consumption questionnaire was used to document the subjects’ self-reported habitual caffeine consumption (Shohet & Landrum, 2001). The results revealed that all participants were light caffeine consumers (< 60 mg per day, ~1 cup of coffee). Subjects were fully informed of any risks and discomforts associated with the experiments before giving their informed written consent to participate. The study was approved by the local Research Ethics Committee.

**Preliminary Testing**

Before the onset of the experiment participants underwent a physical examination including rest and exercise ECG (Cosmed T12, Italy). They performed an incremental cycling test in an electromagnetically braked cycle ergometer (Cardiotest 100, Seca, Germany) to determine their maximal aerobic capacity (VO₂max). After a 5 min warm-up at 100 W, participants began cycling at 125 W with increments of 25 W each minute to volitional fatigue. Gas exchange data were collected using an automated breath by breath system (Quark b2, Cosmed, Italy) and averaged every 15 s. Maximal oxygen uptake (i.e., VO₂max) was defined as the highest plateau in oxygen consumption (two successive maximal readings within 0.15 L · min⁻¹) that occurred despite increases in workload. Data resulting from this test were used to set the exercise workload of each participant during the experimental trials.

**Experimental Design.**

A double-blind, placebo-controlled experimental design was used, with all subjects serving as their own controls. All participants were tested on five different occasions, separated by at least 3 days to allow caffeine washout. In each occasion, participants arrived to the laboratory in the early morning (i.e., before 8 a.m.) and received either 0 (placebo) 0.5, 1.5, 3.0, or 4.5 mg of caffeine per kg of body weight, 1h before exercising for 60 min at 75% of their VO₂max. These caffeine doses were chosen because they are habitual caffeine doses consumed by recreational, amateur and professional sportsmen (Froiland et al., 2004; Kristiansen et al., 2005; Magkos & Kavouras, 2005). Environmental conditions remained thermoneutral (22 °C and 40% relative humidity) during the whole experiment.

After exercise, participants rested supine for 180 min...
while a blood sample was taken and heart rate (HR), blood pressure (BP), and ventilator parameters were monitored, at 60-min intervals. Caffeine (Durvitan, Seid, Spain) was provided in capsules filled with the corresponding dose normalized by body weight. In the trial without caffeine ingestion (i.e., 0 mg·kg\(^{-1}\)), subjects ingested the same number of capsules with the same appearance, but filled with 1 g of dextrose. An alphanumeric code was assigned to each trial to prevent subjects and investigators of knowing the caffeine dose tested. This code was unveiled after the analysis of the variables.

**Experimental Protocol**

Participants were asked to refrain from ingesting any caffeine source (i.e., coffee, tea, cola drinks, and chocolate) 48 hr before the experimental trial. In addition, subjects were asked to refrain from performing intense exercise during the 24 hr before and to replicate the same meal 3 hr before arriving to the laboratory. Trials took place approximately at the same time of day to avoid an influence of circadian rhythm on the cardiovascular or metabolic variables (Bessot et al., 2007) and under the same environmental conditions (room temperature; i.e., \(\sim 22^\circ\text{C}\)). Upon arrival to the laboratory subjects lied down on a stretcher during 20 min. Then a 22-G catheter (Teflon; BD Insyte, Becton Dickinson, Spain) was inserted into an antecubital vein. The catheter was frequently flushed with 3–4 ml of 0.9% sterile saline to ensure patency. After that, the caffeine dose or placebo assigned for the trial was ingested and participants rested for 60 min. Following, subjects cycled continuously for 60 min interspersed with measurements of maximal cycling power using three 4-s all-out sprints (Coso & Mora-Rodríguez, 2006). Data concerning the exercise portion of the protocol have been presented and discussed elsewhere (Del Coso et al., 2010). The exercise intensity (75% \(\text{VO}_{2\text{max}}\)) and oxygen consumption were not different among trials (mean of 2722 ± 694 ml·kg\(^{-1}\)·min\(^{-1}\)). Once the exercise protocol was concluded, participants ate a light snack (284 kcal; 36 g of carbohydrates, 3.3 g of protein and 14 g of fat) and drank water to fully recover the amount of fluid lost during exercise (40.5 L). Thereafter, participants rested for 180 min on a stretcher, while HR, BP, and ventilator parameters were monitored during 4 min periods at the end of each hour. Blood samples were taken just before the 4 min measurement battery.

**Heart Rate and Blood Pressure**

Heart rate (HR) was measured using a heart rate monitor (RS 400, Polar, Finland). Systolic (SBP) and diastolic blood pressure (DBP) were measured in the right arm, in triplicate, using an automated blood pressure monitor (Tango, Suntech Med. Instruments, North Carolina, USA). Mean arterial pressure (MAP) was calculated as \((\{2 \times DBP\} + SBP)/3\).

**Ventilatory Parameters and Substrate Oxidation**

Oxygen consumption (\(\text{VO}_2\)) carbon dioxide production (\(\text{CO}_2\)), ventilation (\(V_e\)) tidal volume (\(V_t\)) and respiratory frequency (\(R_e\)) were assessed using a computerized open-circuit spirometry (Quark b2, Cosmed, Italy). Data were collected during the last 4 min of each hour during the 3 hr recovery period. Energy Expentiture (EE) and substrate oxidation were calculated based on Brouwer formulee (Brouwer, 1957):

\[
\text{EE (Kcal \cdot min}^{-1}\text{)} = [(3.869 \times \text{VO}_2) + (1.195 \times \text{VCO}_2)]
\]

Fat oxidation (g · min\(^{-1}\)) = (1.67 × VO\(_2\)) – (1.67 × VCO\(_2\))

Carbohydrate oxidation (g · min\(^{-1}\)) = (4.55 × VCO\(_2\)) – (3.21 × VO\(_2\))

with VO\(_2\) and VCO\(_2\) expressed in L · min\(^{-1}\).

**Blood Variables**

Blood samples (5 mL) were taken at the end of each hour during the 3-hr postexercise period, right before collection of the other variables. A portion of the blood was allowed to clot in serum tubes (Z Serum Sep Clot Activator Vacuette, Greiner Bio-One GmbH, Austria) and the remaining blood was mixed with ethylenediaminetetraacetic acid in polyethylene tubes and then spun at 2000 × g for 10 min in a refrigerated (4 °C) centrifuge (MPW-350R, Med. Instruments, Poland). The plasma and serum portions of the blood were stored at –80 °C for future analysis. Plasma caffeine levels were analyzed using an Agilent Technologies HPLC 1200 system (Santa Clara, CA) coupled to a triple quadrupole ion trap mass spectrometer (MS; API 4000, QTRAP, AB SCIEX, Framingham, MA US). Blood serum samples were analyzed in duplicate for glucose ([Glu]\(_{\text{serum}}\)) using an enzymatic glucose oxidase assay (Enzymatic Glucose Reagent, Thermostcientific, USA). Lactate concentration ([Lac]\(_{\text{serum}}\)) using an end-point reaction that involved lactate dehydrogenase and detection of NADH (Hohorst, 1965), and free fatty acids (FFA) using an enzymatic colorimetric method (WAKO Chemical Germany). All the measurements were performed using a multichannel spectrometer plate reader (Versamax, Molecular Devices, USA).

**Statistical Analysis.**

Data were analyzed using a two-way ANOVA (caffeine dose × time) with repeated measures. After a significant \(F\) test (Geisser-Greenhouse correction for the assumption of sphericity), differences between means were identified by using Tukey’s HSD post hoc procedure. The Pearson’s correlation coefficient was used to establish relationship between variables. The significance level was set at \(p < .05\). The data were analyzed using the software package SPSS v.19.0. The results presented are means ± SD unless otherwise is indicated.
Results

Postexercise responses to caffeine ingestion were not different between our men and women and thus data have been pooled and analyzed as a group. Caffeine plasma levels (Table 1) were elevated in a dose-response pattern after exercise and remained at that level during the 3-hr postexercise period. Total REE of the 3-hr postexercise period rose 15% above placebo with the ingestion of 4.5 mg·kg⁻¹ of caffeine (233 ± 58 vs. 202 ± 49 kcal; p < .05; Figure 1). However, this increase in caloric expenditure did not produce a difference in substrate utilization and the percent of fat or carbohydrates oxidized remained similar among trials (Table 2). V̇E (Figure 1) and V̇T (Table 2) were also increased when ingesting 4.5 mg·kg⁻¹ of caffeine compared with placebo (9.2 ± 2.7 L·min⁻¹ and 0.67 ± 0.29 L·breaths⁻¹ vs. 7.8 ± 1.5 L·min⁻¹ and 0.56 ± 0.2 L·breaths⁻¹ respectively, p < .05), although there were no differences in ṘE (Table 2). The increases in ventilation correlated with the increases in REE and V̇T when all trials were considered (r = .72 and 0.45, respectively; p < .05; Figure 2).

HR and MAP during the 3-hr postexercise period were not different among trials (Table 3). Neither, [Glu]serum, [Lac]serum or FFA showed significant differences among trials during the 3-hr postexercise period (Table 3).

Discussion

It is a common practice to ingest caffeine before exercise to benefit from its ergogenic effect. Caffeine effects persist after exercise mostly if exercise is short duration (≤ 60 min) due to its prolonged biological half-life (Kamimori et al., 2002). While there is abundant information on the cardiovascular and metabolic consequences of caffeine ingestion at rest, information is scarce when caffeine ingestion is followed by exercise. We currently investigated the metabolic and cardiorespiratory postexercise response to caffeine ingestion before exercise. We selected a range of caffeine doses from 0.5 mg·kg⁻¹ of body mass to 4.5 mg·kg⁻¹ of body mass, which include the more common doses used in recreational and competitive sports (Froiland et al., 2004; Kristiansen et al., 2005; Magkos & Kavouras, 2005). The main findings of this study were: a) the consumption of 4.5 mg·kg⁻¹ of body mass of caffeine, before 60 min of intense cycling rose significantly (i.e., 15%) resting energy expenditure (REE) during 3-hr postexercise; b) the higher REE was associated with higher ventilation (V̇E) and tidal volume. While heart rate, mean arterial pressure, and substrate utilization were not affected by caffeine, REE and V̇E appeared to increase in a dose-dependent manner.

It is well accepted that caffeine has a thermogenic effect at rest (Acheson et al., 1980; Ahrens et al., 2007; Phung et al., 2010; Westerterp-Plantenga et al., 2006). Nevertheless, information about the effects of preexercise caffeine ingestion on postexercise energy expenditure is scarce. To the best of our knowledge, only three studies have investigated the postexercise thermogenic effects of preexercise ingestion of caffeine. Chad and Quigley (Chad & Quigley, 1989) observed an increased energy expenditure (i.e., 8%), fat oxidation and blood FFA during the 1 hr postexercise (90 min of treadmill exercise at 55% VO₂max) that followed preexercise caffeine ingestion (5 mg·kg⁻¹ of body mass). Likewise, Donnelly and McNaughton’s work (Donnelly & McNaughton, 1992) showed increased REE (8%) with the preexercise ingestion of 5 mg·kg⁻¹ of body mass 1 hr after cycling 90 min at 55% VO₂max. We also report elevations in REE with the ingestion of our highest caffeine dose (i.e., 4.5 mg·kg⁻¹ of body mass). However, our subjects’ FFA levels were not significantly elevated and neither their fat oxidation. This could be due to the effect of the snack provided after exercise. Likely the insulin response to the ingested carbohydrate blunted lipolysis and therefore fat oxidation (Horowitzi et al., 1999).

Astorino’s group (Astorino et al., 2011) recently reported that a dose of 6 mg·kg⁻¹ of caffeine, ingested preexercise, increased postexercise REE also by 15% when measured 75 min after a bout of resistance exercise. In our data REE was also elevated by 15% for three hours after continuous exercise. Thus it appears that exercise mode (endurance vs. resistance) does not alter the postexercise elevations in REE. Unfortunately, Astorino et al. did not explore other variables associated with the increase in REE. Thus, it is unknown if ventilation was also associated with the increased REE after caffeine ingestion and resistance exercise.

The association found between the increase in postexercise REE and V̇E suggests that the extra cost of breathing was behind the increased REE. An elevation in V̇E after caffeine ingestion has been previously reported by other investigators during both, rest (D’Urzo et al., 1990) and during exercise (Bell et al., 1999; D’Urzo et al., 1990). D’Urzo et al. (1990) measured the ventilatory response at rest under progressive hyperoxic hypcapnia and isocapnic hypoxia to produce higher ventilation response. In that study it was found that after the ingestion of 8.6 mg·kg⁻¹ of body mass of caffeine V̇E increased above the control trial. As in the current study, they observed that the higher V̇E at rest (7.4–10.5 L·min⁻¹) was caused by a higher V̇t (0.74–0.94 L·breaths⁻¹), with little role for respiratory frequency (ṘV). At rest, in a supine position, expiration is passive and inspiratory muscles demand most of the energy for breathing. A more forceful contraction of the inspiratory muscles (i.e., diaphragm, intercostals, and sternocleidomastoids) may result in an elevated cost of breathing (West, 2012).

D’Urzo and colleagues (1990) discussed that the ventilatory changes induced by caffeine ingestion may be associated to either, a bronchodilator effect or a stimulant effect on the respiratory muscles. However, a bronchodilator effect does not seem to be associated with caffeine ingestion. Powers et al. (1986) found no differences in forced vital capacity and forced expired volume after a dose of 7 mg·kg⁻¹ of caffeine ingestion. In turn, it has also been shown that caffeine supplied to
infants enhanced their ventilatory muscle strength (Kassim et al., 2009). It is then possible that caffeine may enhance inspiratory muscle recruitment by altering the medulla oblongata signals to recruit more inspiratory muscle. Alternatively caffeine may directly stimulate force generation in each inspiration raising V̇ ̇ through a local muscle effect as it has been speculated to take place in skeletal muscle (Mora-Rodriguez et al., 2012; Tarnopolsky & Cupido, 2000).

As previously shown by Graham and Spriet (1995), caffeine ingestion has a dose-response effect on plasma catecholamines. Although the authors dispel the concept that caffeine ergogenic effect is mediated by increased plasma epinephrine, the postexercise metabolic and ventilator effects of caffeine-induced elevations in plasma catecholamines are, to our knowledge, unclear. Epinephrine increases muscle contraction force and carbohydrate oxidation which could have mediated the increased ventilatory response and energy expenditure presently found after the highest caffeine dose (4.5 mg · kg−1). Thus, not having data on plasma catecholamines is a limitation of this study that is worth to mention.

In summary, an oral dose of 4.5 mg·kg−1 of caffeine per body mass is required to affect postexercise metabolism, raising resting energy expenditure by 15%. This increase seemed to be mediated by higher ventilation through an elevated tidal volume. In contrast, blood glucose, free fatty acids, fat, and carbohydrate oxidation were not significantly affected by preexercise caffeine ingestion. Preexercise caffeine ingestion ranging from 0.5 to 4.5 mg·kg−1 of body mass did not have a clear cardiovascular postexercise effects with no changes on blood pressure or heart rate in our young-fit subjects.

Novelty Statement
Caffeine ingested preexercise as an ergogenic aid has metabolic consequences during the 3 hr postexercise that have not been previously considered. A caffeine dose of 4.5 mg·kg−1 of body mass raises postexercise resting energy expenditure by 15% in association with increased ventilation and tidal volume. More importantly, this increase in energy expenditure does not take place with lower caffeine doses (i.e., 1.5, and 3 mg · kg−1) that nonetheless could also result in ergogenic effects.

Practical Application
The use of caffeine before exercise in doses of 4.5 mg·kg−1 of body mass or higher raises postexercise energy expenditure without any adverse cardiovascular effect. However, the magnitude of the increase in energy expenditure (31 kcals) although statistically significant, is small and the consequences for sport nutrition or body weight regulation remains to be determined.

Acknowledgments
The study was designed by VEF-E, JC, NH, JFO and RM-R; data were collected and analyzed by VEF-E, JC, NH, JFO, and RM-R; data interpretation and manuscript preparation were undertaken by VEF-E and RM-R. GM and JMG run the biochemical analysis of caffeine in blood samples. All authors approved the final version of the paper. The authors wish to thank the participants for their invaluable contribution to the study. This study was supported by a grant from the Junta de Comunidades de Castilla-La Mancha (PEII10-0215-3058). Valentín E. Fernández-Ellas was supported by a predoctoral fellowship from the Junta de Comunidades de Castilla-La Mancha. The authors of this study declare that they have no financial, professional, or other personal interest of any nature in any product, service and/or company that could be construed as influencing the position presented in this manuscript.

References


Figure 1 — Energy expenditure and ventilation during 3 hr postexercise with different caffeine ingestion doses. Data are mean ± SD. *Different from 0 mg kg⁻¹, control trial.
Figure 2 — A) Relationship between ventilation (VE) and energy expenditure during 3 hr postexercise. B) Relationship between ventilation (VE) and tidal volume (VT) during 3 hr postexercise. Pearson correlation (r) from 12 subjects in five trials.

Table 1 Plasma Caffeine Levels (ng · ml⁻¹) During the 3 Hr Postexercise Period

<table>
<thead>
<tr>
<th>Group</th>
<th>1 hr postexercise</th>
<th>2 hr postexercise</th>
<th>3 hr postexercise</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 mg·kg⁻¹</td>
<td>0.13 ± 0.19</td>
<td>0.10 ± 0.13</td>
<td>0.10 ± 0.15</td>
</tr>
<tr>
<td>0.5 mg·kg⁻¹</td>
<td>0.78 ± 0.51</td>
<td>0.65 ± 0.32</td>
<td>0.60 ± 0.33</td>
</tr>
<tr>
<td>1.5 mg·kg⁻¹</td>
<td>2.18 ± 0.90</td>
<td>2.20 ± 0.91</td>
<td>2.06 ± 0.88</td>
</tr>
<tr>
<td>3.0 mg·kg⁻¹</td>
<td>3.82 ± 1.85</td>
<td>3.54 ± 1.23</td>
<td>3.82 ± 1.34</td>
</tr>
<tr>
<td>4.5 mg·kg⁻¹</td>
<td>6.32 ± 2.47</td>
<td>6.23 ± 2.78</td>
<td>6.24 ± 2.60</td>
</tr>
</tbody>
</table>

Note. Values are Mean ± SD
*Different from all previous doses (p < .05).

Table 2 Substrate Oxidation, Tidal Volume (VT) and Respiratory Frequency (RF) During the 3-Hr Postexercise Period

<table>
<thead>
<tr>
<th>Group</th>
<th>Fat Oxidation (%)</th>
<th>CHO Oxidation (%)</th>
<th>VT (L·breath⁻¹)</th>
<th>RF (breath · min⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 mg·kg⁻¹</td>
<td>78.7 ± 0.15</td>
<td>21.3 ± 0.15</td>
<td>0.56 ± 0.20</td>
<td>15.5 ± 4.7</td>
</tr>
<tr>
<td>0.5 mg·kg⁻¹</td>
<td>73.5 ± 0.17</td>
<td>26.3 ± 0.17</td>
<td>0.57 ± 0.26</td>
<td>15.4 ± 4.3</td>
</tr>
<tr>
<td>1.5 mg·kg⁻¹</td>
<td>68.8 ± 0.13</td>
<td>31.2 ± 0.13</td>
<td>0.58 ± 0.21</td>
<td>15.1 ± 3.7</td>
</tr>
<tr>
<td>3.0 mg·kg⁻¹</td>
<td>70.6 ± 0.20</td>
<td>29.4 ± 0.20</td>
<td>0.61 ± 0.25</td>
<td>15.5 ± 3.9</td>
</tr>
<tr>
<td>4.5 mg·kg⁻¹</td>
<td>72.4 ± 0.24</td>
<td>27.6 ± 0.24</td>
<td>0.67 ± 0.29</td>
<td>15.2 ± 3.4</td>
</tr>
</tbody>
</table>

Note. Values are mean ± SD.
*Different from 0 mg·kg⁻¹ (p < .05).
Table 3  Heart Rate, Blood Pressure and Blood Concentration of Glucose, Lactate and Free Fatty Acids During the 3-Hr Postexercise Period

<table>
<thead>
<tr>
<th>Dose (mg·kg⁻¹)</th>
<th>HR (beats·min⁻¹)</th>
<th>MAP (mmHg)</th>
<th>[Glu]₆₇₄serum (mmol·L⁻¹)</th>
<th>[Lac]₆₇₄serum (mmol·L⁻¹)</th>
<th>FFA (mmol·L⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 mg·kg⁻¹</td>
<td>68 ± 11</td>
<td>84.1 ± 1.9</td>
<td>4.9 ± 0.4</td>
<td>1.2 ± 0.3</td>
<td>0.38 ± 0.11</td>
</tr>
<tr>
<td>0.5 mg·kg⁻¹</td>
<td>68 ± 12</td>
<td>83.6 ± 1.7</td>
<td>4.9 ± 0.6</td>
<td>1.2 ± 0.2</td>
<td>0.43 ± 0.16</td>
</tr>
<tr>
<td>1.5 mg·kg⁻¹</td>
<td>69 ± 11</td>
<td>83.5 ± 2.0</td>
<td>4.9 ± 0.5</td>
<td>1.3 ± 0.3</td>
<td>0.37 ± 0.15</td>
</tr>
<tr>
<td>3.0 mg·kg⁻¹</td>
<td>71 ± 12</td>
<td>86.3 ± 2.0</td>
<td>5.0 ± 0.4</td>
<td>1.4 ± 0.2</td>
<td>0.44 ± 0.20</td>
</tr>
<tr>
<td>4.5 mg·kg⁻¹</td>
<td>71 ± 13</td>
<td>86.0 ± 2.0</td>
<td>5.1 ± 0.4</td>
<td>1.3 ± 0.3</td>
<td>0.52 ± 0.18</td>
</tr>
</tbody>
</table>

Note: Values are mean ± SD. HR = heart rate, MAP = mean arterial pressure, [Glu]₆₇₄serum = serum glucose concentration, [Lac]₆₄serum = serum lactate concentration, FFA = blood free-fatty acid concentration.